![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
University of Wisconsin, Madison |
---|---|
Information provided by: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00802438 |
A drug (mepolizumab) that reduces allergic inflammation will affect the function of allergy cells called eosinophils which are produced by the body in response to allergen exposure.
Condition | Intervention |
---|---|
Asthma |
Biological: mepolizumab |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study |
Official Title: | Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab |
Estimated Enrollment: | 20 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | August 2013 |
Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Mepolizumab: Experimental
up to 3 monthly doses of 750mg i.v. mepolizumab
|
Biological: mepolizumab
up to three monthly doses of 750mg i.v. mepolizumab
|
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mary Jo M Jackson, BSN | (608) 263-0524 | mmj@medicine.wisc.edu |
Contact: Cheri A Swenson, BS | (608) 262-5189 | cas@medicine.wisc.edu |
United States, Wisconsin | |
University of Wisconsin- Madison | Recruiting |
Madison, Wisconsin, United States, 53792-9988 | |
Contact: Cheri A Swenson, BS 608-262-5189 cas@medicine.wisc.edu | |
Contact: Mary Jo Jackson, BSN (608) 263-0524 mmj@medicine.wisc.edu | |
Sub-Investigator: Loren Denlinger, MD, PhD | |
Principal Investigator: Nizar N Jarjour, MD |
Principal Investigator: | Nizar N Jarjour, MD | University of Wisconsin, Madison |
Responsible Party: | University of Wisconsin- Madison ( Board of Regents of the Universtiy of Wisconsin System ) |
Study ID Numbers: | H-2007-0311 |
Study First Received: | December 4, 2008 |
Last Updated: | December 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00802438 History of Changes |
Health Authority: | United States: Food and Drug Administration |
asthma allergic inflammation IL-5 |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Bronchial Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity Inflammation |
Hypersensitivity Lung Diseases, Obstructive Pathologic Processes Immune System Diseases Respiratory Tract Diseases Bronchial Diseases |
Lung Diseases Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity Inflammation |